A multivariable model adjusting for baseline factors associated with survival showed superior OS with taxanes relative to ARS inhibitors when AR-V7–positive CTCs were detected pretherapy (hazard ratio, 0.24 95% CI, 0.10-0.57 P = .035).Ĭonclusions and Relevance The results validate CTC nuclear expression of AR-V7 protein in men with mCRPC as a treatment-specific biomarker that is associated with superior survival on taxane therapy over ARS-directed therapy in a clinical practice setting. There were statistically significant differences in OS but not in PTPC, time on therapy, or rPFS for patients with or without pretherapy AR-V7–positive CTCs treated with a taxane. Overall, resistant PTPC were seen in 65 of 112 samples (58%) without detectable AR-V7–positive CTCs prior to ARS inhibition. Patients whose samples had AR-V7–positive CTCs before ARS inhibition had resistant posttherapy PSA changes (PTPC), shorter rPFS, shorter time on therapy, and shorter OS than those without AR-V7–positive CTCs. AR-V7–positive CTCs were found in 34 samples (18%), including 3% of first-line, 18% of second-line, and 31% of third- or greater line samples. Results Overall, of 193 prospectively collected blood samples from 161 men with mCRPC, 191 were evaluable (128 pre-ARS inhibitor and 63 pretaxane). Main Outcomes and Measures Prostate-specific antigen (PSA) response, time receiving therapy, radiographic progression-free survival (rPFS), and overall survival (OS). Between December 2012 and March 2015, blood was collected and processed from patients with progressive mCRPC immediately prior to new line of systemic therapy. Objective To determine if pretherapy nuclear androgen-receptor splice variant 7 (AR-V7) protein expression and localization on circulating tumor cells (CTCs) is a treatment-specific marker for response and outcomes between ARS inhibitors and taxanes.ĭesign, Setting, and Participants For this cross-sectional cohort study at Memorial Sloan Kettering Cancer Center, 265 men with progressive mCRPC undergoing a change in treatment were considered 86 were excluded because they were not initiating ARS or taxane therapy and 18 were excluded for processing time constraints, leaving 161 patients for analysis. Importance A critical decision in the management of metastatic castration-resistant prostate cancer (mCRPC) is when to administer an androgen receptor signaling (ARS) inhibitor or a taxane. Meaning Pretherapy CTC nuclear expression of AR-V7 protein in men with mCRPC is a treatment-specific biomarker predicting superior overall survival for taxane therapy over ARS inhibitors in a clinical practice setting, warranting prospective validation. In a multivariable model incorporating line of therapy and other clinical features, AR-V7 status showed significant treatment-specific interaction with taxane administration. Question Can the measurement of the nuclear androgen-receptor splice variant 7 (AR-V7) protein in circulating tumor cells (CTCs) be a treatment-specific biomarker in metastatic castration-resistant prostate cancer (mCRPC) at therapeutic decision points in the first-line, second-line, or third or greater line setting?įindings In this cross-sectional cohort study, mCRPC patients with pre-androgen receptor signaling (ARS) inhibitor AR-V7–positive CTCs had resistant prostate-specific antigen responses, shorter time on therapy, shorter radiographic progression-free survival, and inferior overall survival. Shared Decision Making and Communication.
Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.